A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients
Condition: Mild to Moderate Atopic Dermatitis Interventions: Drug: IN-A002 Ointment 0.3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 1% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 3% or IN-A002 Placebo Ointment; Drug: IN-A002 Ointment 5% or IN-A002 Placebo Ointment; Dr ug: IN-A002 Ointment 1%; Drug: IN-A002 Ointment 3%; Drug: Elidel Cream 1% (pimecrolimus) Sponsor: HK inno.N Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials